Samuel C R Sherratt

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 14

Top Topics

Cardiovascular Disease

Top Venues

Current atherosclerosis reports

Journal of the American Heart Association

Cardiovascular research

European journal of preventive cardiology

This page only lists publications with an associated author ORCID identifier.

Publications

Samuel C R Sherratt, Peter Libby, Hazem Dawoud, Deepak L Bhatt, R Preston Mason
Eicosapentaenoic Acid Improves Endothelial Nitric Oxide Bioavailability Via Changes in Protein Expression During Inflammation. Journal of the American Heart Association 13 (14) (2024)
Samuel C R Sherratt, R Preston Mason, Peter Libby, Phillippe Gabriel Steg, Deepak L Bhatt
Do patients benefit from omega-3 fatty acids? Cardiovascular research 119 (18) (2024)
Samuel C R Sherratt, Peter Libby, Hazem Dawoud, Deepak L Bhatt, R Preston Mason
Eicosapentaenoic Acid Improves Endothelial Nitric Oxide Bioavailability Via Changes in Protein Expression During Inflammation. Journal of the American Heart Association (2024)
Samuel C R Sherratt, Peter Libby, Hazem Dawoud, Deepak L Bhatt, R Preston Mason
Eicosapentaenoic Acid Improves Endothelial Nitric Oxide Bioavailability Via Changes in Protein Expression During Inflammation. Journal of the American Heart Association 13 (14) (2024)
Samuel C R Sherratt, Peter Libby, Hazem Dawoud, Deepak L Bhatt, R Preston Mason
Eicosapentaenoic Acid Improves Endothelial Nitric Oxide Bioavailability Via Changes in Protein Expression During Inflammation. Journal of the American Heart Association 13 (14) (2024)
Samuel C R Sherratt, R Preston Mason, Peter Libby, Phillippe Gabriel Steg, Deepak L Bhatt
Do patients benefit from omega-3 fatty acids? Cardiovascular research 119 (18) (2024)
Samuel C R Sherratt, Peter Libby, Deepak L Bhatt, R Preston Mason
Comparative Effects of Mineral Oil, Corn Oil, Eicosapentaenoic Acid, and Docosahexaenoic Acid in an In Vitro Atherosclerosis Model. Journal of the American Heart Association (2023)
Samuel C R Sherratt
REDUCE-IT, Biomarkers, and Confirmation Bias: Are We Missing the Forest for the Trees? European journal of preventive cardiology (2023)
Samuel C R Sherratt
Letter by Sherratt Regarding Article, "Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy". Circulation 146 (20) (2022)
Samuel C R Sherratt, Peter Libby, Matthew J Budoff, Deepak L Bhatt, R Preston Mason
Role of Omega-3 Fatty Acids in Cardiovascular Disease: the Debate Continues. Current atherosclerosis reports 25 (1) (2022)
Samuel C R Sherratt, Peter Libby, Matthew J Budoff, Deepak L Bhatt, R Preston Mason
Role of Omega-3 Fatty Acids in Cardiovascular Disease: the Debate Continues. Current atherosclerosis reports (2022)
Samuel C R Sherratt, Peter Libby, Matthew J Budoff, Deepak L Bhatt, R Preston Mason
Role of Omega-3 Fatty Acids in Cardiovascular Disease: the Debate Continues. Current atherosclerosis reports 25 (1) (2022)
Samuel C R Sherratt, Peter Libby, Matthew J Budoff, Deepak L Bhatt, R Preston Mason
Role of Omega-3 Fatty Acids in Cardiovascular Disease: the Debate Continues. Current atherosclerosis reports 25 (1) (2022)
Samuel C R Sherratt, Peter Libby, Matthew J Budoff, Deepak L Bhatt, R Preston Mason
Role of Omega-3 Fatty Acids in Cardiovascular Disease: the Debate Continues. Current atherosclerosis reports 25 (1) (2022)